IMAC Holdings
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 4
- Market Cap
- -
- Introduction
IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. Its services include medical treatments, regenerative medicine, physical medicine, physical therapy, spinal decompression and chiropractic manipulation. The company was founded by Matthew C. Wallis, Jason William Brame and Jeffrey S. Ervin in August 2000 and is headquartered in Franklin, TN.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia
- Conditions
- Bradykinesia
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- IMAC Holdings, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04385056
- Locations
- 🇺🇸
IMAC Regeneration Center, Paducah, Kentucky, United States
🇺🇸Ozzie Smith IMAC Regeneration Center, Chesterfield, Missouri, United States
🇺🇸David Price IMAC Regeneration Center, Brentwood, Tennessee, United States
News
Ignite Proteomics Partners with Vanderbilt to Advance Breast Cancer Immunotherapy Biomarker Discovery
Ignite Proteomics and Vanderbilt University Medical Center have launched a one-year research collaboration to characterize protein-signaling pathways that help breast tumor cells evade immune system detection.
Ignite Proteomics' RPPA Assay Drives Complete Response in HER2-Negative Breast Cancer
• Ignite Proteomics launches a novel precision oncology assay using Reverse Phase Protein Array (RPPA) technology for breast cancer treatment decisions. • A case study demonstrated a complete response in a metastatic triple-negative breast cancer patient treated with trastuzumab deruxtecan (T-DXd) after RPPA identified HER2 expression. • The RPPA assay uniquely measures both the expression and activated protein drug target levels in breast tumors, improving targeted therapy effectiveness. • This clinically validated assay represents a significant advancement in personalized oncology care, potentially impacting patient outcomes.